Cancer pain management: newer perspectives on opioids and episodic pain.
Am J Hosp Palliat Care
; 15(1): 13-22, 1998.
Article
en En
| MEDLINE
| ID: mdl-9468974
Cancer pain is significantly undertreated, but the current armamentarium of opioids and other analgesics are such that no cancer patient should be in pain. The guidelines for the treatment of cancer pain suggest that a long-acting, preferably oral, opioid be administered around the clock for persistent baseline pain, along with a short-acting oral opioid for episodes of breakthrough pain. Morphine is the gold standard for ATC opioid treatment, and OTFC is emerging as a potent agent for the management of breakthrough pain. The careful assessment and management of persistent cancer pain and breakthrough pain will help realize the goal of optimal pain management for all cancer patients.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Dolor
/
Dimensión del Dolor
/
Analgésicos Opioides
/
Neoplasias
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Am J Hosp Palliat Care
Asunto de la revista:
ENFERMAGEM
Año:
1998
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos